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ABSTRACT 
Sometimes immediate onset of action is required than conventional treatment in many patients. Among all dosage forms tablet is the 
most popular dosage form existing today because of its convenience of self-administration, compactness and easy manufacturing. to 
overcome these drawbacks, immediate release dosage form has emerged as alternative oral dosage forms. Immediate drug release 
dosage forms disintegrate quickly after administration with enhanced rate of dissolution. The basic approach used in development 
tablets is the use of superdisintegrants like Cross linked Polyvinylpyrrolidone or crospovidone (Polyplasdone), Sodium starch 
glycolate (Primogel, Explotab), carboxymethylcellulose (Croscarmellose) etc. In this field immediate release liquid dosage forms 
and parenteral dosage form have also been introduced for treating patients. The development of immediate release therapy also 
provides an opportunity for a line extension in the marketplace, a wide range of drugs e.g., anticoagulant and other drugs can be 
considered candidates for this dosage form. The development of immediate release therapy also provides an opportunity for a line 
extension in the marketplace, a wide range of drugs e.g., anticoagulant and other drugs can be considered candidates for this dosage 
form. 
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INTRODUCTION 
In that present study and research novel drug delivery 
systems are developed for expanding indications, 
extending product life cycles and generating 
opportunities. Oral administration is the most popular 
route for systemic effects due to its ease of ingestion, 
pain, avoidance, versatility and most importantly patient 
compliance. The development of enhanced oral protein 
delivery technology by immediate release tablets which 
may release the drugs at an enhanced rate are very 
promising for the delivery of poorly soluble drugs high 
molecular weight protein and peptide.
1, 2
  The oral route 
remains the perfect route for the administration of 
therapeutic agents because the low cost of therapy, 
manufacturing and ease of administration lead to high 
levels of patient compliance. Many patients require 
quick onset of action in particular therapeutic condition 
and consequently immediate release of medicament is 
required. It is estimated that 50% of the population is 
affected by this problem, which results in a high 
incidence of ineffective therapy. 
Immediate release tablets are those which disintegrate 
rapidly and get dissolved to release the medicaments. 
Immediate release may be provided for by way of an 
appropriate pharmaceutically acceptable diluent or 
carrier, which diluent or carrier does not prolong, to an 
appreciable extent, the rate of drug release and/or 
absorption. 
2, 3 
  This term excludes formulations which 
are adapted to provide for “modified”, “controlled”, 
“sustained”, “prolonged”, “extended” or “delayed” 
release of drug. Release term includes the provision (or 
presentation) of drug from the formulation to the 
gastrointestinal tract, to body tissues and/or into 
systemic circulation. 
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Anatomy and physiology of stomach  
 
     
                         Figure 1: Anatomy of stomach 
The stomach is part of the digestive system and is 
connected to the: 
 Esophagus – a tube-like organ that connects the 
mouth and throat to the stomach. The area where 
the esophagus joins the stomach is called the 
gastroesophageal (GE) junction. 
 Small intestine (small bowel) – a long tube-like 
organ that extends from the stomach to the colon 
(large intestine or large bowel). The first part of the 
small intestine is called the duodenum, and it is this 
part that is connected to the stomach. 
 The stomach is divided into 5 regions: The cardia is 
the first part of the stomach below the esophagus. It 
contains the cardiac sphincter, which is a thin ring 
of muscle that helps to prevent stomach contents 
from going back up into the esophagus. 
 The fundus is the rounded area that lies to the left of 
the cardia and below the diaphragm. 
 The body is the largest and main part of the 
stomach. This is where food is mixed and starts to 
break down
3, 1
. 
 The antrum is the lower part of the stomach. The 
antrum holds the broken-down food until it is ready 
to be released into the small intestine. It is 
sometimes called the pyloric antrum. 
 The pylorus is the part of the stomach that connects 
to the small intestine. This region includes the 
pyloric sphincter, which is a thick ring of muscle 
that acts as a valve to control the emptying of 
stomach contents (chyme) into the duodenum (first 
part of the small intestine). The pyloric sphincter 
also prevents the contents of the duodenum from 
going back into the stomach.
 2
 
Pharmacokinetics 
It is the study of absorption, distribution, metabolism 
and excretion. After absorption, drug attains therapeutic 
level and therefore elicits pharmacological effect, so 
both rate and extend of absorption is important. In 
conventional dosage form there is delay in disintegration 
and therefore dissolution is fast. Drug distribution 
depends on many factors like tissue permeability, 
perfusion rate, binding of drug to tissue, disease state, 
drug interaction etc. Duration and intensity of action 
depends upon rate of drug removal from the body or site 
of action i.e. biotransformation. Decrease in liver 
volume, regional blood flow to liver reduces the 
biotransformation of drug through oxidation, reduction 
and hydrolysis. Excretion by renal clearance is slowed, 
thus half-life of renal excreted drugs increase.
 3, 4
 
Pharmacodynamics 
Drug reception interaction impaired in elderly as well as 
in young adult due to undue development of organ.                                                         
Decreased ability of the body to respond reflexive 
stimuli, cardiac output, and orthostatic hypotension may 
see in taking antihypertensive like prazosin. Decreased 
sensitivity of the CVS to α-adrenergic agonist and 
antagonist. Immunity is less and taken into 
consideration while administered antibiotics.
 1, 4
 
            
Figure 2: Absorption of Drug from the GIT.
 3
 
 Altered response to drug therapy-elderly show 
diminished bronchodilator effect of theophylline shows 
increased sensitivity to barbiturates. 
Concomitant illnesses are often present in elderly, which 
is also taken into consideration, while multiple drug 
therapy prescribed.                                             
Research workers have clinically evaluated drug 
combination for various classes’ cardiovascular agents, 
diuretics, anti-hypertensive etc. for immediate release 
dosage forms. The combination choice depends on 
disease state of the patient. 
Desired Criteria for Immediate Release Drug 
Delivery System: 
Immediate release dosage form should- 
2
 
 It should not leave minimal or no residue in the 
mouth after oral administration.  
 Exhibit low sensitivity to environmental condition 
as humidity and temperature.  
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  Be manufactured using conventional processing 
and packaging equipment at low cost.  
 Rapid dissolution and absorption of drug, which 
may produce rapid onset of action        
 In the case of solid dosage it should dissolve or 
disintegrate in the stomach within a short period.  
  In the case of liquid dosage form it should be 
compatible with taste masking.  
  Be portable without fragility concern.  
  Have a pleasing mouth feel. 
Merits of Immediate Release Drug Delivery System:  
Adaptable and amenable to existing processing and 
packaging machinery
5
  
 Cost- effective  
 Improved solubility of the pharmaceutical 
composition; Decreased disintegration and 
dissolution times for immediate release oral dosage 
forms.  
 Improved compliance/added convenience  
 Improved stability, bioavailability  
 Suitable for controlled/sustained release actives  
 Allows high drug loading.  
 Ability to provide advantages of liquid medication 
in the form of solid preparation. 
6
 
GENERAL EXCIPIENTS USED IN IMMEDIATE 
RELEASE TABLETS 
Ideal characteristics of excipients
6
 
 They must be free of any unacceptable 
microbiological load.  
 They must be color compatible, should not change 
shade of color in the formulation.  
 If product is classified as food, the diluents and 
other excipients must be approved food additives.  
 They must not have an adverse effect on the 
bioavailability of the products. They must be non-
toxic with no pharmacological activity and 
acceptable to the regulatory agencies in the 
countries where the product is to be marketed.  
 They must be commercially available in an 
acceptable grade in countries where the product is 
to be manufacture.  
  Cost effective.  
  They must be physiologically inert.  
  They must be physically and chemically stable by 
themselves and in combination with other drugs and 
tablet components.
 6 
 
Table 1: Lists of different excipients used in the design of tablets 
Excipients Functions Examples 
Diluents Used as filler designed make up the required 
bulk of the tablet. 
Lactose, starch, mannitol, 
sucrose, sorbitol etc. 
Binders and 
Adhesives 
These are used to produce cohesive compact, 
either in dry or wet form. 
Hydroxy propyl methyl cellulose, acacia, 
starch, cellulose derivative etc. 
Disintegrants Used to facilitate a breakup of the tablet. Starch, clays, cellulose, alginate, povidone etc 
Lubricants Used to reduce the friction during tablet 
ejection between the walls of die cavity. 
Stearic acid, stearic acid salts, polyethylene 
glycol, talc, waxes etc. 
Antiadherants Used to reduce sticking or adhesion of any 
tablet granules or powder to the faces of 
punches or die wall. 
Talc, polyethylene glycol, hydrogenated 
castor oil, glyceryl behenate etc. 
Glidants or flow 
promoters 
Used to promote flow of the tablet granules or 
powder material by reducing friction within 
particles. 
Silica derivatives, talc, corn starch etc. 
Colors, flavors and 
sweeteners 
Used to enhance the Organoleptic properties 
and acceptability of the product. 
FD & C, D&C dyes and lakes, banana, bubble 
gum, strawberry, vanilla flavors, aspartame, 
neotame, saccharin, mannitol etc. 
 
A. Disintegrants: 
As disintegrants sodium starch glycolate, sodium 
carboxymethyl cellulose, calcium carboxymethyl 
cellulose, croscarmellose sodium, Crospovidone, 
polyvinyl polypyrrolidone, methyl cellulose, 
microcrystalline cellulose, powdered cellulose, lower 
alkyl-substituted hydroxypropyl cellulose, polacrilin 
potassium, starch, pregelatinized starch, sodium alginate, 
and mixtures thereof. The amount of disintegrant 
included in the dosage form will depend on several 
factors, including the properties of the dispersion, the 
properties of the porosigen and the properties of the 
disintegrants selected. Generally, the disintegrant will 
comprise from 1% w/w to 25% w/w of the dosage form.
 
3
 
Mechanism of tablet Disintegration  
The tablet breaks to primary particles by one or more of 
the mechanisms listed below:
 4
  
1) By capillary action  
2) By swelling  
3) Because of heat of wetting  
4) Due to disintegrating particle/particle repulsive force 
5) Due to deformation  
6) Due to release of gases  
7) By enzymatic action  
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Table 2: Classification of superdisintegrants 
Sr no. Structure type Description Trade name 
1. Modified starches 
(Sodium starch glycolate) 
Sodium carboxy methyl starch, the carboxymethyl groups 
induced hydrophilicity and cross-linking reduces solubility. 
Explotab 
Primojel 
2. Modified cellulose 
(Crosscarmallose NF) 
Sodium carboxy methyl cellulose which has been cross-linked 
to render the material insoluble. 
Ac-Di-Sol 
Nymcel 
Solutab 
3. Cross-linked 
polyvinylpyrrolidone 
(Crosspovidone) 
Cross-linked polyvinylpyrrolidone, the high molecular weight 
and cross-linking render the material insoluble in water. 
Crospovidone 
Kollidon 
Polyplasdone 
 
B. Binder  
Binder is a material used to bind other materials 
together. Microcrystalline cellulose (MCC) is 
commonly used as a filler-binder in direct compression 
because of its good bonding properties. Other 
commonly used binders in direct compression include 
starches and their derivatives, such as pregelatinised and 
granulated starches.  
C. Surfactants  
One very useful class of excipients is surfactants, 
preferably present from 0 to 10 % w/w. Suitable 
surfactants include fatty acid and alkyl sulfonates; 
commercial surfactants such as benzalkonium chloride, 
dioctyl sodium sulfosuccinate, polyoxyethylene sorbitan 
fatty acid esters, natural surfactants such as sodium 
taurocholic acid, lecithin, and other phospholipids and 
mono and diglycerides; and mixtures thereof. Such 
materials can advantageously be employed to increase 
the rate of dissolution by, for example, facilitating 
wetting, or otherwise increase the rate of drug release 
from the dosage form.
 9
  
D. pH Modifiers  
Inclusion of pH modifiers such as acids, bases, or 
buffers may also be beneficial in an amount of from 0 to 
10 % w/w. Acidic pH modifiers (e.g., acids such as 
citric acid or succinic acid) retard the dissolution of the 
pharmaceutical composition when the dispersion 
polymer is anionic. Alternatively, basic pH modifiers 
(e.g., sodium acetate or amines) enhance the rate of 
dissolution of the same types of pharmaceutical 
composition.
 8
   
E. Diluents  
Examples of other matrix materials, fillers, or diluents 
include lactose, mannitol, xylitol, dextrose, sucrose, 
sorbitol, compressible sugar, microcrystalline cellulose 
(MCC), powdered cellulose, starch, pregelatinized 
starch, dextrates, dextran, dextrin, dextrose, 
maltodextrin, calcium carbonate, dibasic calcium 
phosphate, tribasic calcium phosphate, calcium sulfate, 
magnesium carbonate, magnesium oxide, poloxamers, 
polyethylene oxide, hydroxypropyl methyl cellulose 
(HPMC) and mixtures thereof.
 9
  
F. Lubricants  
Examples of lubricants include calcium stearate, 
glyceryl monostearate, glyceryl palmitostearate, 
hydrogenated vegetable oil, light mineral oil, 
magnesium stearate, mineral oil, polyethylene glycol, 
sodium benzoate, sodium lauryl sulfate, sodium stearyl 
fumarate, stearic acid, talc and zinc stearate. 
10
 
G. Glidants   
Examples of glidants include silicon dioxide, talc and 
cornstarch. A glidant is a substance that is added to a 
powder to improve its flowability. A glidant will only 
work at a certain range of concentrations. Above a 
certain concentration, the glidant will in fact function to 
inhibit flowability (which means that there's a critical 
concentration to be used if increasing powder's 
flowability is intended with respect to the glidant and 
the powder properties). In tablet manufacture, glidants 
are usually added just prior to compression.
 10
  
TECHNIQUE USED FOR THE PREPARATION 
OF IMMEDIATE RELEASE TABLETS     
Several Technologies are available to manufacture 
immediate release tablets. The most common 
preparation methods are moulding, lyophilisation or 
freeze drying, direct compression, spray drying and 
sublimation. 
 Tablet molding technique  
  Direct compression technique  
  Granulation technique  
 Direct  compression method 
In this method, tablets are compressed directly from the 
mixture of the drug and excipients without any 
preliminary treatment. The mixture to be compressed 
must have adequate flow properties and cohere under 
pressure thus making pretreatment as wet granulation 
unnecessary. Few drugs can be directly compressed into 
tablets of acceptable quality. A type of disintegrant and 
its proportion are of prime importance. The other factors 
to be considered are particle size distribution, contact 
angle, pore size distribution, tablet hardness and water 
absorption capacity. All these factors determine the 
disintegration. The disintegrant addition technology is 
cost effective and easy to implement at industrial level.  
 Dry granulation                                                
In dry granulation process the powder mixture is 
compressed without the use of heat and solvent. The two 
basic procedures are to form a compact of material by 
compression and then to mill the compact to obtain 
granules. Two methods are used for dry granulation.
 14, 12
 
a. Slugging process 
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Granulation by slugging is the process of compressing 
dry powder of tablet formulation with tablet press 
having die cavity large enough in diameter to fill 
quickly. The accuracy or condition of slug is not too 
important. Only sufficient pressure to compact the 
powder into uniform slugs should be used. Once slugs 
are produced they are reduced to appropriate granule 
size for final compression by screening and milling.
 11, 13
 
 
 
 
   
  
 
 
 
 
 
 
 
 
 
Figure 3: Slugging Process. 
 
b. Roller compaction 
The compaction of powder by means of pressure roll can also be accomplished by a machine called chilsonator. Unlike 
tablet machine, the chilsonator turns out a compacted mass in a steady continuous flow. The powder is fed down 
between the rollers from the hopper which contains a spiral auger to feed the powder into the compaction zone. Like 
slugs, the aggregates are screened or milled for production into granules
15, 12
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                  Dispensing of API & Excipients  
Sifting  
Mixing in Blender  
Compression by using large size punches i.e. 15mm 
or more & make slugs (applying pressure)  
Screening & Milling of slugs & break into required 
granules size  
Lubrication & Final compression 
                                     Sifting
                              Mixing in Blender 
Compression by using large size punches i.e. 15mm or 
more & make slugs (applying pressure) 
Screening & Milling of slugs & break into required granules 
size 
Lubrication & Final compression 
                           Dispensing of API & Excipients 
                            Sifting & Mixing in Blender 
                Mixed blend feed into hopper of roller compactor 
Applying pressure on powder via rollers when it comes 
between two moving rollers & collect slugs in collecting duct 
Again collected powder feed into hopper & repeat same process 
two-three times until near about 70-80% slugs are not formed 
Screening & Milling of slugs & break into required granules size 
                          Lubrication & Final compression 
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 Tablet molding 
In this technology, water-soluble ingredients are used so 
that tablet disintegrate and dissolve rapidly. The powder 
blend is moistened with a hydro alcoholic solvent and is 
molded in to tablet using compression pressure lower 
than used in conventional tablets compression. The 
solvent is then removed by air-drying. Molded tablets 
have a porous structure that enhances dissolution. Two 
problems commonly encountered are mechanical 
strength and poor taste masking characteristics. Using 
binding agents such as sucrose, acacia or poly vinyl 
pyrrolidone can increase the mechanical strength of the 
tablet. To overcome poor taste masking characteristic 
Van Scoik incorporated drug containing discrete 
particles, which were formed by spray congealing a 
molten mixture of hydrogenated cottonseed oil, sodium 
bicarbonate, lecithin, polyethylene glycol and active 
ingredient into a lactose based tablet triturate form.
 14
 
 Wet granulation method 
Wet granulation is a process of using a liquid binder to 
lightly agglomerate the powder mixture. The amount of 
liquid has to be properly controlled, as over-wetting will 
cause the granules to be too hard and under-wetting will 
cause them to be too soft and friable. Aqueous solutions 
have the advantage of being safer to deal with than 
solvent-based systems but may not be suitable for drugs 
which are degraded by hydrolysis. 
Procedure  
 The active ingredient and excipients are weighed 
and mixed.  
 The wet granulate is prepared by adding the liquid 
binder–adhesive to the powder blend and mixing 
thoroughly. Examples of binders/adhesives include 
aqueous preparations of corn starch, natural gums 
such as acacia, and cellulose derivatives such as 
methyl cellulose, gelatin and povidone.  
 Screening the damp mass through a mesh to form 
pellets or granules.  
 Drying the granulation. A conventional tray-dryer 
or fluid-bed dryer are most commonly used.  
 After the granules are dried, they are passed through 
a screen of smaller size than the one used for the 
wet mass to create granules of uniform size.  
 Low shear wet granulation processes use very 
simple mixing equipment, and can take a 
considerable time to achieve a uniformly mixed 
state. High shear wet granulation processes use 
equipment that mixes the powder and liquid at a 
very fast rate, and thus speeds up the manufacturing 
process. Fluid bed granulation is a multiple-step wet 
granulation process performed in the same vessel to 
pre-heat, granulate, and dry the powders. It is used 
because it allows close control of the granulation 
process.
 10
 
 Mass-Extrusion  
This technology involves softening the active blend 
using the solvent mixture of water-soluble polyethylene 
glycol and methanol and subsequent expulsion of 
softened mass through the extruder or syringe to get a 
cylinder of the product into even segments using heated 
blade to form tablets. The dried cylinder can also be 
used to coat granules for bitter drugs and thereby 
achieve taste masking.
 16
 
PROBLEMS IN TABLET MANUFACTURING 
An ideal tablet should be free from any visual defect or 
functional defect. The advancements and innovations in 
tablet manufacture have not decreased the problems, 
often encountered in the production, instead have 
increased the problems, mainly because of the 
complexities of tablet presses; and/or the greater 
demands of quality. An industrial pharmacist usually 
encounters number of problems during manufacturing. 
Majority of visual defects are due to inadequate fines or 
inadequate moisture in the granules ready for 
compression or due to faulty machine setting. 
Functional defects are due to faulty formulation. Solving 
many of the manufacturing problems requires an in-
depth knowledge of granulation processing and tablet 
presses and is acquired only through an exhaustive study 
and a rich experience.  
Following are the defects that are found during tablet 
manufacturing: 
5, 15, 17
 
1. Weight variation  
2. Capping  
3. Lamination / Laminating  
4. Cracking  
5. Chipping  
6. Sticking / Picking  
7. Mottling  
8. Double impression  
 
 
Figure 3: problems in tablet manufacturing 
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EVALUATION OF IMMEDIATE RELEASE 
TABLETS                        
The blend is evaluated by following tests.
 17, 18, 19
 
1. Angle of repose  
2. Bulk density  
3. Tapped density  
4. Carr’s index  
5. Hausner’s Ratio 
1. Angle of repose  
Angle of repose was determined by using funnel 
method. The accurately weighed blend was taken in a 
funnel. The height of the funnel was adjusted in such a 
way that the tip of the funnel just touches the apex of the 
heap of blend. The drug excipient blend was allowed to 
flow through the funnel freely on to the surface. The 
diameter of the powder cone was measured and angle of 
repose was calculated using the following equation.
 12 
Tan = h/r  
Where h and r are the height and radius of the powder 
conc. 
 
Figure 4: Measurement of angle of repose (Fixed 
Funnel method). 
2. Bulk density  
Bulk density was determined by pouring a weighed 
quantity of tablet blend into graduated cylinder and 
measuring the height. Bulk density is the ratio of mass 
of tablet blend to bulk volume. It was calculated in 
gm/cm3 by the formula.  
Bulk Density (BD) = Weight of granules (m) /untapped 
volume of granules (v).  
Here; m = weight of powder or granules (gm)  
v = Bulk Volume (cm.3)  
3. Tapped Density  
Tapped density is ratio of mass of tablet blend to tapped 
volume of tablet blend. Accurately weighed amount of 
tablet blend poured in graduated cylinder and height is 
measured. Then cylinder was allowed to 100tap under 
its own weight onto a hard surface. The tapping was 
continued until no further change in height was noted it 
was calculated in gm/cm3 by the formula. 
Tapped Density (TD) = Weight of granules (m) /tapped 
volume of granules (v). 
 Here; m = weight of powder or granules (gm)  
v = Tapped Volume (cm.3) 
Compressibility Index  
The Compressibility Index of the blends was determined 
by Carr’s compressibility index.  
4. Carr’s compressibility index (%) = Compressibility 
is the ability of powder to decrease in volume under 
pressure using bulk density and tapped density the 
percentage compressibility of powder were determined, 
which is given as carr’s compressibility index.  
It is indirectly related to the relative flow rate. Carr’s 
compressibility index was determined by the given 
formula.  
Carr’s Index (%) = [(TBD-LBD) X 100] / TBD  
5. Hauser’s ratio = Hausner’s ratio indicates the flow 
properties of powder and measured by the ratio of 
tapped density to bulk density. Hausner’s ratio was 
determined by the given Formula. 
Hausner’s Ratio =Tapped density/ Poured density  
Hausner’s ratio <1.25 – Good flow = 20% Carr 1.25 – 
Poor flow =33% Carr  
Compression  
Mixed Blends is compressed by direct compression 
method using Cadmach single punch machine. Caput 
punches and die (8 mm.) were used in this study. 
In-vitro Evaluation of the prepared tablets 
These tests are as following  
1. Appearance  
2. Thickness  
3. Hardness  
4. Weight variation  
5. Friability  
6. Disintegration  
7. Drug content  
8. In vitro Dissolution  
9. Stability studies 
1. Appearance  
The general appearance of tablet is its visual identity 
and all over elegance, shape, color, surface textures. 
These all parameters are essential for consumer 
acceptance.  
2. Thickness  
The thickness of the tablets was determined by using 
vernier calipers. Randomly 10 tablets selected were used 
for determination of thickness that expressed in  
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Mean± SD and unit is mm.  
3. Hardness  
The hardness of tablet is an indication of its strength 
against resistance of tablets to capping, abrasion or 
breakage under conditions of storage, transportation and 
handling before usage. Measuring the force required to 
break the tablet across tests it. Hardness of 10 tablets 
(randomly) from whole tablet batch was determined by 
Monsanto hardness tester. Hardness measured in 
kg/cm
2
. 
4. Weight variation  
The weight variation test is carried out in order to ensure 
uniformity in the weight of tablets in a batch. The total 
weight of 20 tablets randomly from whole batch was 
determined and the average was calculated. The 
individual weights of the tablets were also determined 
accurately and the weight variation was calculated.  
5. Friability test  
Friability is the loss of weight of tablet in the container 
due to removal of fine particles from the surface during 
transportation or handling. Roche friabilator was 
employed for finding the friability of the tablets. For 
tablets with an average weight of 0.65 g or less take a 
sample of whole tablets corresponding to about 6.5 g 
and for tablets with an average weight of more than 0.65 
g take a sample of 10 whole tablets. Roche friabilator is 
rotated at 25rpm for 4 minutes for 100rounds. The 
tablets were dedusted and weighed again. The 
percentage of weight loss was calculated using the 
formula 
%f= W0-W1/W0*100  
%f = Percentage friability  
W0 = Initial weight (Before test)  
W1 = Final weight (After test) 
6. Disintegration test  
The USP device to rest disintegration was six glass 
tubes that are “3 long, open at the top, and held against 
10” screen at the bottom end of the basket rack 
assembly. One tablet is placed in each tube and the 
basket rack is poisoned in 1 liter beaker of distilled 
water at 37± 2 o C, such that the tablets remain below 
the surface of the liquid on their upward movement and 
descend not closer than 2.5cm from the bottom of the 
beaker.  
7. Drug content  
10 tablets were powdered and 100mg drug equivalent 
powder dissolved in suitable media buffer or 0.1N HCl. 
Volume of the solution made up to 100ml by that media. 
Solution was filtered and diluted 100times and analyzed 
spectrophotometrically and further Calculation carried 
out to determine drug content in one tablet. 
8. In vitro drug release studies  
The immediate release tablets are subjected to in vitro 
drug release studies in pH 6.8 phosphate buffer or 0.1N 
HCl for 30 minutes to access the ability of the 
formulation for providing immediate drug delivery. 
Drug release studies were carried out in dissolution test 
apparatus using specified volume 900ml of dissolution 
media maintained at 37±100C. The tablets are kept in 
the cylindrical basket or directly placed in medium with 
paddle then rotated at 100 rpm. 5ml of the sample from 
the dissolution medium are withdrawn at each time 
interval (5, 10, 15 & 30 minutes) and 5ml of fresh 
medium was replaced each time. The samples were 
filtered and from the filtrate 1ml was taken and diluted 
to 10ml. These samples were analyzed 
spectrophotometrically and further calculation was 
carried out to get drug release. The drug released data 
were plotted and tested with zero order (Cumulative % 
drug released Vs time), First order (Log % Remained Vs 
time). The in vitro dissolution kinetic parameters, 
dissolution rate constants, correlation coefficient and 
dissolution efficiency were calculated. 
Dissolution Profile  
The compositions of the present invention preferably are 
immediate release compositions from which about 50% 
of the micronized drug is dissolved in vitro within about 
15 minutes, more preferably at least about 80% of the 
drug is dissolved in vitro within about 30 minutes, and 
still more preferably at least about 90% of the e is 
dissolved in vitro within about 45 minutes using 1% 
sodium dodecyl sulfate (SDS) in water as the dissolution 
medium at 37° C. 
9. Stability study  
Stability is defined as the ability of a particular drug or 
dosage form in a specific container to remain within its 
physical, chemical, therapeutic, and toxicological 
specifications. Drug decomposition or degradation 
occurs during storage, because of chemical alteration of 
the active ingredients or due to product instability, 
lowering the concentration of the drug in the dosage 
form. Stability study of the dosage form must include a 
section for product characterization and another section 
to study the product stability during storage. 
Formulations are evaluated for their appearance, 
possible weight gain in drug content thickness, flatness, 
folding endurance, tensile strength, moisture content and 
moisture uptake, and in-vitro release study by keeping 
dosage form in different temperature and humidity 
condition after a specified time. The stability study 
indicates that the formulation is quite stable at different 
conditions of storage. 
Recommended long-term and accelerated storage 
conditions  
Study Storage condition Minimum time period covered 
by data at submission  
Long term-25°C ± 2°C/60% RH ± 5% RH or 30°C ± 
2°C/65% RH ± 5% RH 12 months  
Intermediate-30°C ± 2°C/65% RH ± 5% RH 6 months  
Accelerated-40°C ± 2°C/75% RH ± 5% RH 6 months. 
CONCLUSION  
A new dosage format, the immediate release 
pharmaceutical form has been developed which offers 
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the combined advantages of ease of dosing and 
convenience of dosing. These tablets are designed to 
release the medicaments with an enhanced rate. To 
fulfill these medical needs, formulation have devoted 
considerable efforts to developing a novel types of tablet 
dosages for oral a administration, one that disintegrant 
and dissolve rapidly with enhanced dissolution. An 
extension of market exclusivity, which can be provide 
by immediate release dosage form leads to increase 
revenue, while also targeting underserved and under –
treated patent population. Due to the constraints of the 
current technologies there is a need for improved 
manufacturing processes for immediate release 
pharmaceutical form that are mechanically strong, 
allowing ease of handling and packaging and with 
production costs similar to that of conventional tablets.
  
REFERENCES 
1. Leon Lachman, Herbert A, Liberman and Joseph L. Kaing: 
The Theory And Practice Of Industrial Pharmacy: 293-303.  
2. Bhavin Patel, Dr. M.S. Ranawat, Dr. Chetan Singh Chauhan, 
Jaimin Modi Design, Development and Characterization of 
Immediate Release Tablet of Pioglitazone. JPSBR, March 
April 2013; 3(2): 91-99.  
3. Aulton`S Pharmaceutics, The Design & Manufacture Of 
Medicines,Biopharmaceutics And Pharmacokinetics, A 
Treatise, Second Edition, Valabh Prakashan, 315-384. Syed 
A, et al, “Immediate Release Drug Delivery Systems: A 
Review”, International journals of Biopharmaceutical & 
Toxicological Research., 2001.  
4.  Ansel`S Pharmaceutical Dosage Forms & Drug Delivery 
Systems, Eighth Edition, 227-260. 
5. Rana AS, Hari Kumar SL, Manufacturing Defects of Tablets 
- A Review, Journal of Drug Delivery and Therapeutics, 
2013; 3(6):200-206. doi:10.22270/jddt.v3i6.722 
6. Vaishali Kilor, Nidhi Sapkal, Awari J, Shewale B. 
Development And Characterization Of Enteric-Coated 
Immediate-Release Pellets Of Aceclofenac By 
Extrusion/Spheronization Technique Using Carrageenan As 
A Pelletizing Agent, AAPS Pharmscitech, 2010; 11(1): 336-
343. 
7. Manish Jaimini* and Saurabh Rawat- A Review on 
Immediate Release Drug Delivery System, RJPBCS, April-
June 2013; 4(2): 1726. 
8. Rawlins EA. Tablets and Capsules. In: Bentleys.Text book of 
pharmaceutics. New Delhi: All India Traveller Publishers., 
2006; 234-310 
9. Cooper, J., Gunn, C., “Powder flow and compaction”, In: 
Carter SJ, eds. Tutorial Pharmacy. CBS Publishers and 
Distributors, New Delhi, India. 1986; 211-233. 
10. . Dedhiya et al, “Lercanidipine immediate release 
compositions” United States Patent Application 2006. 
11. Dandare MS et al. Bilayer tablet: A Novel approach for 
immediate release of telmisartan and hydrochlorthaizide 
combination. International Journal of Pharmacy & 
Technology April 2012; 4(1): 3970-3983. 
12. Margret Chandira. R., Jayakar.B, Pasupathi, A. Chakrabarty 
and BL Maruya P: Design, Development and Evaluation of 
Immediate Release Atorvastatin and Sustained Release 
Gliclazide Tablets, Journal of Pharmacy Research. 2009; 
6(2). 
13.  Bhowmick et al, Fast Dissolving Tablet: An Overview, 
Journal of Chemical and Pharmaceutical Research, 2009, 
1(1): 163-177 
14. A Gupta, AK Mishra, V Gupta, P Bansal, R Singh and AK 
Singh: Review Article, Recent Trends Of Fast Dissolving 
Tablet - An Overview Of Formulation Technology, 
International Journal Of Pharmaceutical & Biological 
Archives., 2010; 1(1): 1 – 10.  
15. Reddy LH: Fast Dissolving Drug Delivery Systems: A 
Review Of The Literature, IJPS. 2002: 331-336  
16. R. Natarajan, Rohit Vaishnani,and NN. 
Rajendran,Formulation and Evaluation   Immediate Release 
Tablets of Paroxetine HCl Using Different  
Superdisintegrants, International Journal of Research in 
Pharmaceutical and Biomedical  Sciences,Vol. 2 (3) Jul – 
Sep 2011. 
17. Garg A, Gupta M, Taste masking and formulation 
development & evaluation of mouth dissolving tablets of 
levocetrizine dihydrochloride. Journal of Drug Delivery and 
Therapeutics, 2013; 3(3):123-130. 
doi:10.22270/jddt.v3i3.514 
18. Sood R et al. Immediate release antihypertensive valsartan 
oral tablet: A Review. Journal of Scientific Research in 
Pharmacy May 2012; 1(2): 20-26. 
19. Srinivas Pannala, Mahalaxmi Rathnanand,Preparation and in 
vitro evaluation of Nizatidine immediate release tablets, 
International Journal of PharmTech Research, Vol.3, No.3 pp 
1688-1692, July-Sept 2011 
 
 
